Ann: Half Yearly Report and Accounts, page-6

Poor old Imugene. Just can't get any love in the market, despite the recent complete responses in trial. And no wonder. (Understandably) very little discussion of these results for all the many thousands of retail IMU investors.

Difficult to put lipstick on this porcine beauty, but at least they got those silly high general/admin expenses down to more reasonable levels.



A sorry tale:



The "next best thing" showing up in the capital burning decay of what was always just a call option on oncology The probability of success implied by the price of the 'option' at last belies its likely probability of success, hence I am buying more IMU. But I am under no illusion to the continued weight of liabilities from the IP it bought until then. I wonder if many retail investors were:



The more specific explanation of which is indeed in the notes, for example in the intellectual property payments. IMU was always going to be a very expensive hold in terms of cash burn. A decent partnership remains the only quick release from the weight of such business pressures on the share price, for all the short lived share spikes on forthcoming catalysts. Commercialisation is just too far away still at this point and still for all the belief of shareholders, still marginal. Retail investors may consider it shoo-in, but more professional analysts might still put its success in its 4-5 approaches at as little as 10-15% likelihood and the share price implies even less. Its a bit more likely than that IMO.